Literature DB >> 24127738

Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study.

K Büsch1, J F Ludvigsson, K Ekström-Smedby, A Ekbom, J Askling, M Neovius.   

Abstract

BACKGROUND: Regional studies on inflammatory bowel disease (IBD) suggest an increasing prevalence over time, but no nationwide estimate has been published so far. AIM: To estimate the IBD prevalence in 2010 in Sweden overall, by disease, and in specific patient segments.
METHODS: Patients were identified according to international classification codes for ulcerative colitis and Crohn's disease in in-patient care (1987-2010), day surgery and nonprimary out-patient care (1997-2010) in the nationwide Swedish Patient Register.
RESULTS: Requiring two or more diagnoses of IBD in nonprimary care, a total of 61 344 individuals with physician-diagnosed IBD were alive in Sweden in 2010 (mean age 50 years; 51% men), corresponding to a prevalence of 0.65% (95% CI, 0.65-0.66). The prevalence increased with age, and peaked in women at ages 50-59 years and in men at ages 60-69 years. Adding the requirement of IBD as main (vs. main or contributory) diagnosis code, or diagnosis from an internal medicine/gastroenterology/surgery department did not change the prevalence estimate. Prevalence of actively treated disease (defined as two or more IBD-related visits, of which one occurred in 2010, plus at least one dispensed prescription of IBD-related drugs in 2010) was 0.27% (95% CI, 0.27-0.28).
CONCLUSIONS: The Swedish nationwide register-based IBD prevalence was higher compared with previous Swedish and international estimates. While prevalence estimates were robust across different case definitions, once two or more visits were required, only about one-third of prevalent patients were drawing resources from specialised care in 2010.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24127738     DOI: 10.1111/apt.12528

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  36 in total

1.  Association Between Long-term Oral Contraceptive Use and Risk of Crohn's Disease Complications in a Nationwide Study.

Authors:  Hamed Khalili; Fredrik Granath; Karin E Smedby; Anders Ekbom; Martin Neovius; Andrew T Chan; Ola Olen
Journal:  Gastroenterology       Date:  2016-02-23       Impact factor: 22.682

2.  The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database.

Authors:  Sergio Iannazzo; Gianluca Furneri; Federica Demma; Chiara Distante; Simone Parisi; Veronica Berti; Enrico Fusaro
Journal:  Rheumatol Ther       Date:  2016-05-26

3.  Oral Contraceptive Use and Risk of Ulcerative Colitis Progression: A Nationwide Study.

Authors:  Hamed Khalili; Martin Neovius; Anders Ekbom; Jonas F Ludvigsson; Johan Askling; Andrew T Chan; Ola Olen
Journal:  Am J Gastroenterol       Date:  2016-10-11       Impact factor: 10.864

4.  Association between IgA deficiency & other autoimmune conditions: a population-based matched cohort study.

Authors:  Jonas F Ludvigsson; Martin Neovius; Lennart Hammarström
Journal:  J Clin Immunol       Date:  2014-03-02       Impact factor: 8.317

5.  Pyruvate kinase M2 regulates apoptosis of intestinal epithelial cells in Crohn's disease.

Authors:  Qiyun Tang; Qianqian Ji; Weiwei Xia; Liren Li; Jian'an Bai; Runzhou Ni; Yongwei Qin
Journal:  Dig Dis Sci       Date:  2014-05-11       Impact factor: 3.199

6.  Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease.

Authors:  Thomas Cars; Björn Wettermark; Robert Löfberg; Irene Eriksson; Johan Sundström; Mikael Lördal
Journal:  J Crohns Colitis       Date:  2016-01-05       Impact factor: 9.071

7.  Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data.

Authors:  Majed Khraishi; Jelena Ivanovic; Yvonne Zhang; Brad Millson; Marie-Josee Brabant; Katia Charland; John Woolcott; Heather Jones
Journal:  Clin Rheumatol       Date:  2018-05-16       Impact factor: 2.980

8.  Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014.

Authors:  S Ballou; W Hirsch; P Singh; V Rangan; J Nee; J Iturrino; T Sommers; J Zubiago; N Sengupta; A Bollom; M Jones; A C Moss; S N Flier; A S Cheifetz; A Lembo
Journal:  Aliment Pharmacol Ther       Date:  2018-02-07       Impact factor: 8.171

9.  Registers of the Swedish total population and their use in medical research.

Authors:  Jonas F Ludvigsson; Catarina Almqvist; Anna-Karin Edstedt Bonamy; Rickard Ljung; Karl Michaëlsson; Martin Neovius; Olof Stephansson; Weimin Ye
Journal:  Eur J Epidemiol       Date:  2016-01-14       Impact factor: 8.082

10.  An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland.

Authors:  Richard F Pollock; Gorden Muduma
Journal:  Clinicoecon Outcomes Res       Date:  2021-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.